Amount (US$M)



Total: $184.5M (Year total: $605.46M)

Alkermes plc (Dublin)

Biogen Inc. (Cambridge, Mass.)


Following Biogen's review of preliminary gastrointestinal tolerability data from the ongoing clinical program of BIIB-098 (diroximel fumarate)


Argenx NV (Breda, the Netherlands)

Abbvie Inc. (North Chicago)


For achieving the second of two preclinical milestones toward an investigational new drug filing for ARGX-115, which binds specifically to glycoprotein A repetitions predominant that plays a key role in the regulation of production and release of active transforming growth factor beta


Evotec AG (Hamburg, Germany)

Sanofi SA (Paris)


For reaching the second beta cell therapy milestone as part of their diabetes-focused strategic alliance


Galapagos NV (Mechelen, Belgium)

Gilead Sciences Inc. (Foster City, Calif.)


For progression into phase III of the phase IIb/III SELECTION study testing filgotinib in ulcerative colitis


Incyte Corp. (Wilmington, Del.)

Eli Lilly and Co. (Indianapolis)


For FDA approval of a 2-mg dose of the once-daily oral JAK 1/2 inhibitor baricitinib, to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor inhibitors


Mundipharma International Corp. Ltd. (Cambridge, U.K.)

Orexo AB (Uppsala, Sweden)


For the launch of Zubsolv (buprenorphine and naloxone sublingual tablet), for use in the treatment of opioid dependence, in the European Union


Tetraphase Pharmaceuticals Inc. (Watertown, Mass.)

Everest Medicines Ltd. (China)


For filing an application with Chinese regulators to start the phase III trial of lead product eravacycline in complicated intra-abdominal infections



Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.